Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

By: Milan Sheth, M.D., hematology/oncology, MemorialCare Todd Cancer Institute at Long Beach Medical Center MemorialCare is ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.

(Cancer) The FDA approved isatuximab (Sarclisa), in combination with bortezomib (Velcade), lenalidomide (Revlimid), and ...